Tetratherix Limited - Half Year Financial Report FY2026
Tetratherix Limited (ASX: TTX) reported a significant loss of AU$4.62 million for the half-year ending 31 December 2025, an increase from the AU$2.08 million loss during the same period in FY2025. Despite this, the company experienced a substantial boost in revenue, with total income rising to AU$1.79 million, up from AU$459,000. This growth is primarily due to research and development grants as well as interest income. Operating expenses surged by 152%, primarily driven by increased staff costs and investments in the advanced manufacturing facility.
The company remains focused on its long-term growth strategy, with notable milestones achieved, including the execution of a global distribution agreement for its bone regeneration product, Tegenix, with Henry Schein. Additionally, progress was made in clinical trials, including the successful first-in-human insertion of the Tutelix hydrogel spacer. Tetratherix holds a strong cash position of AU$21.6 million, supporting its ongoing R&D and manufacturing expansion.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Tetratherix Limited - Half Year Financial Report FY2026
Tetratherix Limited (ASX: TTX) reported a significant loss of AU$4.62 million for the half-year ending 31 December 2025, an increase from the AU$2.08 million loss during the same period in FY2025. Despite this, the company experienced a substantial boost in revenue, with total income rising to AU$1.79 million, up from AU$459,000. This growth is primarily due to research and development grants as well as interest income. Operating expenses surged by 152%, primarily driven by increased staff costs and investments in the advanced manufacturing facility.
The company remains focused on its long-term growth strategy, with notable milestones achieved, including the execution of a global distribution agreement for its bone regeneration product, Tegenix, with Henry Schein. Additionally, progress was made in clinical trials, including the successful first-in-human insertion of the Tutelix hydrogel spacer. Tetratherix holds a strong cash position of AU$21.6 million, supporting its ongoing R&D and manufacturing expansion.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au